The Inhibitory Fcy -Receptor Iib (Cd32B) Is Highly Expressed On Clonal Plasma Cells From Patients With Systemic Light-Chain (Al) Amyloidosis And Provides A Target For Monoclonal Antibody Therapy

2007 ◽  
pp. 371-373
Author(s):  
S Koenig ◽  
A Boruchov ◽  
J Young ◽  
P Zhou ◽  
R Comenzo ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Light Chain ◽  
Plasma Cells ◽  
Antibody Therapy ◽  
Al Amyloidosis ◽  
Monoclonal Antibody Therapy ◽  
Fcy Receptor

Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement

2020 ◽  
Vol 20 (3) ◽  
pp. 184-189 ◽  
Author(s):  
Amandeep Godara ◽  
Nauman Saleem Siddiqui ◽  
Lisa X. Lee ◽  
Denis Toskic ◽  
Teresa Fogaren ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cardiac Involvement ◽  
Antibody Therapy ◽  
Al Amyloidosis ◽  
Monoclonal Antibody Therapy

scholarly journals CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody–based therapy

Blood ◽  
2008 ◽  
Vol 111 (7) ◽  
pp. 3403-3406 ◽  
Author(s):  
Ping Zhou ◽  
Raymond L. Comenzo ◽  
Adam B. Olshen ◽  
Ezio Bonvini ◽  
Scott Koenig ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Cell Surface ◽  
Light Chain ◽  
Plasma Cells ◽  
Xenograft Model ◽  
B Cell Lymphoma ◽  
Fc Receptor ◽  
Al Amyloidosis ◽  
Light Chain Amyloidosis ◽  
Cell Surface Staining

AbstractDespite advances in therapy, many patients with systemic light-chain amyloidosis (AL) die within 3 years from diagnosis. The humanized 2B6 monoclonal antibody (MoAb) is specific for the low-affinity IgG Fc receptor CD32B and effective in a human CD32B+ B-cell lymphoma murine xenograft model. Because MoAb therapy could improve outcomes in AL, we studied CD32B expression by clonal plasma cells obtained from 48 patients with AL. Transcript profiling showed that expression of CD32B was significantly higher than expression of all other Fc receptor family members. Reverse-transcriptase polymerase chain reaction (RT-PCR) using double-enriched CD138+ plasma cells showed uniform expression of the stable cell surface CD32B1 isoform at diagnosis and relapse, and flow cytometry showed intense CD32B cell surface staining on 99% of CD138+ plasma cells at diagnosis and relapse. These data provide a rationale for the novel therapeutic targeting of CD32B using the humanized 2B6 MoAb in patients with systemic AL-amyloidosis.

scholarly journals Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections

2021 ◽  
Author(s):  
Hilal Ahmad Parray ◽  
Shivangi Shukla ◽  
Reshma Perween ◽  
Ritika Khatri ◽  
Tripti Shrivastava ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Respiratory Infections ◽  
Antibody Therapy ◽  
Monoclonal Antibody Therapy
Sign in / Sign up

Export Citation Format

Share Document